- Home
- FLOC vs PTGX Comparison
FLOC vs PTGX Comparison
Compare FLOC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLOC
- PTGX
- Stock Information
- Founded
- FLOC 1996
- PTGX 2006
- Country
- FLOC United States
- PTGX United States
- Employees
- FLOC N/A
- PTGX N/A
- Industry
- FLOC Metal Fabrications
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- FLOC Industrials
- PTGX Health Care
- Exchange
- FLOC Nasdaq
- PTGX Nasdaq
- Market Cap
- FLOC 2.1B
- PTGX 2.4B
- IPO Year
- FLOC 2025
- PTGX 2016
- Fundamental
- Price
- FLOC $25.97
- PTGX $48.88
- Analyst Decision
- FLOC Strong Buy
- PTGX Strong Buy
- Analyst Count
- FLOC 5
- PTGX 8
- Target Price
- FLOC $33.60
- PTGX $66.50
- AVG Volume (30 Days)
- FLOC 634.6K
- PTGX 1.7M
- Earning Date
- FLOC 03-18-2025
- PTGX 05-06-2025
- Dividend Yield
- FLOC N/A
- PTGX N/A
- EPS Growth
- FLOC N/A
- PTGX N/A
- EPS
- FLOC 10.41
- PTGX 4.23
- Revenue
- FLOC $535,278,000.00
- PTGX $434,433,000.00
- Revenue This Year
- FLOC $58.00
- PTGX N/A
- Revenue Next Year
- FLOC $12.94
- PTGX $8.12
- P/E Ratio
- FLOC $2.50
- PTGX $11.56
- Revenue Growth
- FLOC 119.99
- PTGX 624.05
- 52 Week Low
- FLOC $21.31
- PTGX $24.22
- 52 Week High
- FLOC $30.50
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- FLOC N/A
- PTGX 53.01
- Support Level
- FLOC N/A
- PTGX $51.06
- Resistance Level
- FLOC N/A
- PTGX $53.70
- Average True Range (ATR)
- FLOC 0.00
- PTGX 2.58
- MACD
- FLOC 0.00
- PTGX -0.81
- Stochastic Oscillator
- FLOC 0.00
- PTGX 0.72
About FLOC Flowco Holdings Inc. Class A Common Stock
Flowco Holdings Inc is a provider of production optimization, artificial lift and methane abatement solutions for the oil and natural gas industry. Its technologies include high pressure gas lift (HPGL), conventional gas lift, plunger lift and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions which include rental services and Natural Gas Technologies which include service gas compression parts and equipment sales. Key revenue is generated from Production Solutions.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.